From: TNF-α blockade is ineffective in animal models of established polycystic kidney disease
Study | Genotype | Age at treatment | Animals per arm | Treatments | Administration route | Dose | Schedule | Treatment duration |
---|---|---|---|---|---|---|---|---|
ARPKD rat, short-term therapeutic intervention | PcK/Crljcrl-Pkhd1pck | 4 weeks | 10 | Vehicle | NA | NA | NA | 4 weeks |
PcK/Crljcrl-Pkhd1pck | 4 weeks | 10 | Mozavaptan | i.p. | 0.5, 5, 10 mg/kg | Once, every third day | 4 weeks | |
ARPKD rat, Long-term therapeutic intervention | PcK/Crljcrl-Pkhd1pck | 4 weeks | 10 | Vehicle | NA | NA | NA | 8 weeks |
PcK/Crljcrl-Pkhd1pck | 4 weeks | 10 | Mozavaptan | Milled chow | 0.10% | ad libitum | 8 weeks | |
PcK/Crljcrl-Pkhd1pck | 4 weeks | 10 | Etanercept | i.p. | 5 mg/kg | Once, every third day | 8 weeks | |
ADPKD (PDK2 ws25/-) mouse, therapeutic intervention | PKD2 ws25/- | 12 weeks | 14 | Vehicle | NA | NA | NA | 8 weeks |
PKD2 ws25/- | 12 weeks | 11 | Mozavaptan | Milled chow | 0.10% | ad libitum | 8 weeks | |
PKD2 ws25/- | 12 weeks | 15 | Etanercept | i.p. | 5 mg/kg | Once, every third day | 8 weeks | |
ADPKD (PDK2 ws25/-) mouse, prophylactic intervention | PKD2 ws25/- | 4 weeks | 15 | Vehicle | NA | NA | NA | 8 weeks |
PKD2 ws25/- | 4 weeks | 15 | Mozavaptan | Milled chow | 0.05% | ad libitum | 8 weeks | |
PKD2 ws25/- | 4 weeks | 15 | Etanercept | i.p. | 5, 10 mg/kg | Once, every third day | 8 weeks |